Corona Remedies (NSE:CORONA) Marketable Securities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CORONA Corona Remedies Ltd NSE:CORONA
21 GF Score
Price ₹2,236.10
! 5 Warning Signs
View Full Analysis

What is Corona Remedies Marketable Securities?

Corona Remedies NSE:CORONA +1.60% 21 Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:CORONA with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Corona Remedies's Marketable Securities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Corona Remedies  (NSE:CORONA) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Corona Remedies Marketable Securities Related Terms

Corona Remedies Marketable Securities Historical Data

* Premium members only.

The historical data trend for Corona Remedies's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corona Remedies Marketable Securities Chart

Corona Remedies Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Marketable Securities
59.69 0.00 0.00 0.00

Corona Remedies Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:CORONA
21GF Score
Corona Remedies Ltd NSE:CORONA
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corona Remedies Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹0 Mil mean?
Corona Remedies (NSE:CORONA) has a Marketable Securities of ₹0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Corona Remedies and its competitors.
Is Corona Remedies' Marketable Securities too high?
Corona Remedies' current Marketable Securities is ₹0 Mil. Overall, Corona Remedies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Marketable Securities compare to LLY and JNJ?
Corona Remedies' Marketable Securities of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Corona Remedies and its competitors. Corona Remedies's current Marketable Securities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Marketable Securities of ₹0 Mil. The current Marketable Securities is ₹0 Mil. Corona Remedies' overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corona Remedies Business Description

Other Exchanges 544644:India
Address S. G. Highway, CORONA House, C - Mondeal Business Park, Near Gurudwara, Thaltej, Ahmedabad, GJ, IND, 380 059
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
21GF Score

Get the complete analysis for NSE:CORONA

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,236.10
Price